Cardiovascular pharmacogenetics in the SNP era.

In the past pharmacological agents have contributed to a significant reduction in age-adjusted incidence of cardiovascular events. However, not all patients treated with these agents respond favorably, and some individuals may develop side-effects. With aging of the population and the growing prevalence of cardiovascular risk factors worldwide, it is expected that the demand for cardiovascular drugs will increase in the future. Accordingly, there is a growing need to identify the 'good' responders as well as the persons at risk for developing adverse events. Evidence is accumulating to indicate that responses to drugs are at least partly under genetic control. As such, pharmacogenetics - the study of variability in drug responses attributed to hereditary factors in different populations - may significantly assist in providing answers toward meeting this challenge. Pharmacogenetics mostly relies on associations between a specific genetic marker like single nucleotide polymorphisms (SNPs), either alone or arranged in a specific linear order on a certain chromosomal region (haplotypes), and a particular response to drugs. Numerous associations have been reported between selected genotypes and specific responses to cardiovascular drugs. Recently, for instance, associations have been reported between specific alleles of the apoE gene and the lipid-lowering response to statins, or the lipid-elevating effect of isotretinoin. Thus far, these types of studies have been mostly limited to a priori selected candidate genes due to restricted genotyping and analytical capacities. Thanks to the large number of SNPs now available in the public domain through the SNP Consortium and the newly developed technologies (high throughput genotyping, bioinformatics software), it is now possible to interrogate more than 200,000 SNPs distributed over the entire human genome. One pharmacogenetic study using this approach has been launched by GlaxoSmithKline to identify the approximately 4% of patients who are predisposed to developing a hypersensitivity reaction to abacavir, an anti-HIV agent. Data collected thus far on the HLA locus on chromosome 6 indicate that this approach is feasible. Extended linkage disequilibrium can be detected readily, even across several haplotype blocks, thus potentially reducing the number of SNPs for future whole-genome scans. Finally, a modest number of cases and controls appears to be sufficient to detect genetic associations. There is little doubt that this type of approach will have an impact on the way cardiovascular drugs will be developed and prescribed in the future.

Statistical analysis of DOE EML QAP data from 1982 to 1998.

The historical database from the Environmental Measurements Laboratory's Quality Assessment Program from 1982 to 1998 has been analyzed to determine control limits for future performance evaluations of the different laboratories contracted to the U.S. Department of Energy. Seventy-three radionuclides in four different matrices (air filter, soil, vegetation, and water) were analyzed. The evaluation criteria were established based on a z-score calculation.

Laboratory robotics and artificial intelligence.

Intelligent robots, which incorporate artificial intelligence in their controlling software, are the next step in bringing the laboratory robot to its full potential. The areas currently under study in our laboratory are improved user interfaces for laboratory robotics, the integration of object-oriented databases into robot control programs, and strategies to optimize multi-step procedures. The ultimate goal of this work is the Standard Robotics Method. The Standard Robotics Method we envision would allow a robotic method to be transferred from one laboratory to another.

ARTS: a flexible laboratory instrument control language.

A generalized computer program, ARTS (Analytical Robot Telecommunications Software), has been developed to give the research scientist more flexible control of laboratory robots and instruments. As a stand-alone program, ARTS is a complete laboratory control language. ARTS can also be an extension of other software in either a master or slave mode. As master, ARTS can call on other software to perform certain tasks. In a slave mode, ARTS can act as a sensory extension of the calling software. ARTS is a flexible laboratory control language capable of adapting to changing laboratory requirements.

On robust partial discriminant analysis as a decision-making tool with clinical and analytical chemical data.

Classification is one of the fundamental goals of science and is basic to the diagnosis of disease. Unfortunately, classifying objects (e.g., patients) on the basis of clinical and/or laboratory experimental observations into various groups can be difficult when the groups overlap or contain outlying points. Recently, Broffitt, Randles, and co-workers proposed a procedure, robust partial discriminant analysis (RPDA) for dealing with such problems, but testing of the procedure was limited to Monte Carlo simulation. In this study, RPDA was applied to real data, in order to compare its effectiveness with ordinary discriminant analysis, as well as to determine if RPDA was a suitable procedure to use to classify chemical compounds on the basis of experimental observations and as a tool in the diagnosis of disease (in particular, multiple sclerosis and thyrotoxicosis), with data based on experimental and clinical observations. The resulting RPDA classifications were an improvement over those obtained from ordinary discriminant analysis.